UK pharma major GlaxoSmithKline (LSE: GSK) and its US partner Theravance (Nasdaq: THRX) have started a global Phase III study, known as IMPACT, which will evaluate the efficacy and safety of the ‘closed’ triple combination of FF/UMEC/VI in patients with chronic obstructive pulmonary disease (COPD).
This is the first pivotal Phase III study in a program to evaluate a once-daily closesd triple combination treatment of an inhaled corticosteroid, a long-acting muscarninc antagonist and a long-acting beta-adrenergic agonist in patients with COPD.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze